RT Journal Article
SR Electronic
T1 COVID-19 serological survey using micro blood sampling
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.09.20209858
DO 10.1101/2020.10.09.20209858
A1 Matthews, Melissa M.
A1 Kim, Tae Gyun
A1 Shibata, Satoshi
A1 Shibata, Noriko
A1 Butcher, Christian
A1 Hyun, Jaekyung
A1 Kim, Keon Young
A1 Robb, Theodore
A1 Jheng, Siang Sheng
A1 Narita, Masashi
A1 Mori, Tomoari
A1 Collins, Mary
A1 Wolf, Matthias
YR 2021
UL http://medrxiv.org/content/early/2021/02/11/2020.10.09.20209858.abstract
AB During August 2020, we carried out a serological survey among students and employees at the Okinawa Institute of Science and Technology Graduate University (OIST), Japan, testing for the presence of antibodies against SARS-CoV-2, the causative agent of COVID-19. We used a FDA-authorized 2-step ELISA protocol (1, 2) in combination with at-home self-collection of blood samples using a custom low-cost finger prick-based capillary blood collection kit. Although our survey did not find any COVID-19 seropositive individuals among the OIST cohort, it reliably detected all positive control samples obtained from a local hospital and excluded all negatives controls. We found that high serum antibody titers can persist for at least up to 6.5 months post infection. Among our controls, we found strong cross-reactivity of antibodies in samples from a serum pool from two MERS patients in the anti-SARS-CoV-2-S ELISA. Here we show that a centralized ELISA in combination with patient-based capillary blood collection using as little as one drop of blood can reliably assess the seroprevalence among communities. Anonymous sample tracking and an integrated website created a stream-lined procedure. Major parts of the workflow were automated on a liquid handler, demonstrating scalability. We anticipate this concept to serve as a prototype for reliable serological testing among larger populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Platform Project for Supporting Drug Discovery and Life Science Research (BINDS) from AMED, under grant number JP18am0101076 (to M.W.). We acknowledge financial support by OPG for a larger serological study, as well as direct funding from OIST.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human subject research approval: The experiments were conducted according to a proposal approved by the OIST human subjects ethics committee (application HSR-2020-026). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRequests for further information or raw data should be directed to the corresponding author.